{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:53:41Z","timestamp":1765475621463,"version":"3.48.0"},"reference-count":21,"publisher":"Innovative Healthcare Institute","issue":"3","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>A 62-year-old man presented with a slowly growing, painless lesion on his face. This eventually led to a progressive left-eye vision lesion, and the patient was subsequently diagnosed with advanced basal cell carcinoma (BCC). Of note, BCC involving cranial nerves is extremely rare, making this case unique and important to highlight. Standard treatment options for BCC involve surgery, radiation, or platinum-based chemotherapy. However, targeted therapies such as sonidegib and vismodegib \u2013 sonic hedgehog pathway inhibitors \u2013 have emerged that have been approved for treating BCC, as have anti-PD1 immunotherapies, such as cemiplimab, with their success likely based on the high tumor mutational burden seen in some of these tumors. Epidermal growth factor receptor (EGFR) inhibitors also serve a role in treating this condition as well. Molecular studies on metastatic\/advanced BCC and other rare malignancies may inform treatment therapeutic decisions.<\/jats:p>","DOI":"10.36401\/jipo-23-47","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T19:08:36Z","timestamp":1709579316000},"page":"201-204","source":"Crossref","is-referenced-by-count":0,"title":["Images in Immunotherapy and Precision Oncology: Advanced Basal Cell Carcinoma"],"prefix":"10.36401","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5653-2837","authenticated-orcid":true,"given":"Anagha","family":"Deshpande","sequence":"first","affiliation":[{"name":"1 Mayo Clinic Alix School of Medicine, Scottsdale, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Munoz","sequence":"additional","affiliation":[{"name":"2 Department of Hematology, Mayo Clinic Arizona, Phoenix, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"3 Medical College of Wisconsin, Milwaukee, WI, USA"},{"name":"4 WIN Consortium, Paris, France"},{"name":"5 University of Nebraska, Omaha, NE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22027","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"2024081917352335600_i2590-017X-7-3-201-b01","first-page":"167","article-title":"Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management","volume":"88","author":"Marzuka","year":"2015","journal-title":"Yale J Biol Med"},{"key":"2024081917352335600_i2590-017X-7-3-201-b02","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2147\/DDDT.S325852","article-title":"Current perspectives in the treatment of locally advanced basal cell carcinoma","volume":"16","author":"Gupta","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"2024081917352335600_i2590-017X-7-3-201-b03","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2008.10.005","article-title":"Basal cell carcinoma with intracranial invasion","volume":"60","author":"Kleydman","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2024081917352335600_i2590-017X-7-3-201-b04","first-page":"1553","article-title":"Clinical phase I-II study of cis-dichloro-diammineplatinum(II) given by continuous IV infusion","volume":"62","author":"Salem","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"2024081917352335600_i2590-017X-7-3-201-b05","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0277-5379(90)90262-R","article-title":"Systemic cytotoxic therapy of basal cell carcinoma","volume":"26","author":"Pfeiffer","year":"1990","journal-title":"A review of the literature. Eur J Cancer"},{"key":"2024081917352335600_i2590-017X-7-3-201-b06","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/jamadermatol.2013.3064","article-title":"Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011","volume":"149","author":"Wysong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2024081917352335600_i2590-017X-7-3-201-b07","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1002\/mc.22690","article-title":"Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond","volume":"56","author":"Bakshi","year":"2017","journal-title":"Mol Carcinog"},{"key":"2024081917352335600_i2590-017X-7-3-201-b08","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/jdv.14542","article-title":"Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study","volume":"32","author":"Lear","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024081917352335600_i2590-017X-7-3-201-b09","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"2024081917352335600_i2590-017X-7-3-201-b10","doi-asserted-by":"crossref","first-page":"582866","DOI":"10.3389\/fonc.2020.582866","article-title":"Sonidegib for the treatment of advanced basal cell carcinoma","volume":"10","author":"Brancaccio","year":"2020","journal-title":"Front Oncol"},{"key":"2024081917352335600_i2590-017X-7-3-201-b11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2017.12.009","article-title":"Emerging trends in the treatment of advanced basal cell carcinoma","volume":"64","author":"Migden","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"2024081917352335600_i2590-017X-7-3-201-b12","doi-asserted-by":"crossref","first-page":"e04021","DOI":"10.1002\/ccr3.4021","article-title":"Epidermal growth factor receptor inhibitor in advanced basal cell carcinoma","volume":"9","author":"Amirabadi","year":"2021","journal-title":"Clin Case Rep"},{"key":"2024081917352335600_i2590-017X-7-3-201-b13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7150\/jca.3491","article-title":"Cetuximab in refractory skin cancer treatment","volume":"3","author":"Kalapurakal","year":"2012","journal-title":"J Cancer"},{"key":"2024081917352335600_i2590-017X-7-3-201-b14","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"Stratigos","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024081917352335600_i2590-017X-7-3-201-b15","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1093\/annonc\/mdy412","article-title":"Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics","volume":"29","author":"Nikanjam","year":"2018","journal-title":"Ann Oncol"},{"key":"2024081917352335600_i2590-017X-7-3-201-b16","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/j.jaad.2020.02.052","article-title":"Basal cell carcinoma: management of advanced or metastatic cancer with checkpoint inhibitors and concurrent paradoxical development of new superficial tumors","volume":"82","author":"Cohen","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024081917352335600_i2590-017X-7-3-201-b17","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/2326-6066.CIR-19-0149","article-title":"Microsatellite-stable tumors with high mutational burden benefit from immunotherapy","volume":"7","author":"Goodman","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"2024081917352335600_i2590-017X-7-3-201-b18","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2018.1701","article-title":"Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors","volume":"4","author":"Goodman","year":"2018","journal-title":"JAMA Oncol"},{"key":"2024081917352335600_i2590-017X-7-3-201-b19","doi-asserted-by":"crossref","first-page":"e1404217","DOI":"10.1080\/2162402X.2017.1404217","article-title":"Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies","volume":"7","author":"Goodman","year":"2018","journal-title":"Oncoimmunology"},{"key":"2024081917352335600_i2590-017X-7-3-201-b20","doi-asserted-by":"crossref","first-page":"16037","DOI":"10.1038\/npjgenmed.2016.37","article-title":"Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy","volume":"1","author":"Ikeda","year":"2016","journal-title":"NPJ Genom Med"},{"key":"2024081917352335600_i2590-017X-7-3-201-b21","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3390\/ijms18081663","article-title":"Appearance of new cutaneous superficial basal cell carcinomas during successful nivolumab treatment of refractory metastatic disease: implications for immunotherapy in early versus late disease","volume":"18","author":"Cohen","year":"2017","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/7\/3\/201\/3421049\/i2590-017x-7-3-201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/7\/3\/201\/3421049\/i2590-017x-7-3-201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:33Z","timestamp":1765475313000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/7\/3\/article-p201.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,8,19]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-23-47","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"type":"electronic","value":"2590-017X"},{"type":"print","value":"2666-2345"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}